1-20 of 31
Rebecca Garris, Msc
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Hyper-CVAD and Sequential Blinatumomab in Adults with Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia: Results from a Phase II Study

Nicholas J. Short, MD, Hagop M. Kantarjian, MD, Farhad Ravandi, MBBS, Xuelin Huang, PhD, Alessandra Ferrajoli, MD, Tapan M. Kadia, MD, Philip A. Thompson, MB, MS, Yesid Alvarado, MD, Nitin Jain, MD, Musa Yilmaz, MD, Joseph D. Khoury, MD, Jeffrey L. Jorgensen, MD PhD, Sa A Wang, MD, Steven M. Kornblau, MD, Marina Konopleva, MD PhD, Guillermo Garcia-Manero, MD, Heather M Schroeder, Monica Kwari, BSN, Shilpa Paul, PharmD, Benjamin Nwakanme, Christopher Loiselle, BS, Rebecca Garris, MSc, Susan M. O'Brien, MD, Elias Jabbour, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 9–11.
https://doi.org/10.1182/blood-2020-138565
Published: 2020
Journal Articles

Ultrasensitive Next-Generation Sequencing-Based Measurable Residual Disease Assessment in Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia after Frontline Therapy: Correlation with Flow Cytometry and Impact on Clinical Outcomes

Nicholas J. Short, MD, Hagop M. Kantarjian, MD, Keyur Patel, MD PhD, Steven M. Kornblau, MD, Jeffrey L. Jorgensen, MD PhD, Sa A Wang, MD, Marina Konopleva, MD PhD, Nitin Jain, MD, Partow Kebriaei, MD, Musa Yilmaz, MD, Ghayas C. Issa, MD, Jairo A. Matthews, Munazza Noor, Rebecca Garris, MSc, Farhad Ravandi, MBBS, Elias Jabbour, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 26–28.
https://doi.org/10.1182/blood-2020-141971
Published: 2020
Journal Articles

Reduced-Intensity Chemotherapy with Mini-Hyper-CVD Plus Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: Results from a Phase II Study

Nicholas J. Short, MD, Hagop M. Kantarjian, MD, Farhad Ravandi, MBBS, Xuelin Huang, PhD, Nitin Jain, MD, Tapan M. Kadia, MD, Joseph D. Khoury, MD, Jeffrey L. Jorgensen, MD PhD, Sa A Wang, MD, Yesid Alvarado, MD, Jan A. Burger, MD PhD, Naval Daver, MD, Gautam Borthakur, MD, Courtney D. DiNardo, MD MSCE, Marina Konopleva, MD PhD, Naveen Pemmaraju, MD, Guillermo Garcia-Manero, MD, William G. Wierda, MD PhD, Steven M. Kornblau, MD, Jovitta Jacob, RN, Meagan Rostykus, RN, Monica Kwari, BSN, Caitlin R. Rausch, PharmD, Christopher Loiselle, BS, Anna Milton, Juan Rivera, Rebecca Garris, MSc, Susan M. O'Brien, MD, Elias Jabbour, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 15–17.
https://doi.org/10.1182/blood-2020-138569
Published: 2020
Journal Articles

Prognostic Significance of Genetic Alterations in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Treated with Hyper-CVAD Plus Dasatinib or Hyper-CVAD Plus Ponatinib

Yuya Sasaki, MDPhD, Hagop M. Kantarjian, MD, Nicholas J. Short, MD, Nitin Jain, MD, Koji Sasaki, MD, Farhad Ravandi, MBBS, Marina Konopleva, MD PhD, Guillermo Garcia-Manero, MD, Latasha Little, BS, Curtis Gumbs, Li Zhao, PhD, P Andrew Futreal, PhD, Feng Wang, PhD, Ken Furudate, DDM, PhD, Rebecca Garris, MSc, Koichi Takahashi, MD PhD, Elias Jabbour, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 40–41.
https://doi.org/10.1182/blood-2020-136676
Published: 2020
Journal Articles

Frontline HCVAD with Nelarabine and Peg-Asparaginase in T-Acute Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LBL): Updated Results of a Phase II Trial

Abhishek Maiti, MBBS, Elias Jabbour, MD, Nitin Jain, MD, Gautam Borthakur, MD, Tapan M. Kadia, MD, Jan A. Burger, MD PhD, William G. Wierda, MD PhD, Marina Konopleva, MD PhD, Yesid Alvarado, MD, Nicholas J. Short, MD, Stefan Faderl, Susan M. O'Brien, MD, Alessandra Ferrajoli, MD, Steven M. Kornblau, MD, Naval Daver, MD, Naveen Pemmaraju, MD, Prithviraj Bose, MD, Philip A. Thompson, MB, MS, Joseph D. Khoury, MD, Hayley Balkin, Mary Kelly, Hind Azzawi, Rebecca Garris, MSc, Guillermo Garcia-Manero, MD, Hagop M. Kantarjian, MD, Farhad Ravandi, MBBS
Journal: Blood
Blood (2020) 136 (Supplement 1): 36–39.
https://doi.org/10.1182/blood-2020-136873
Published: 2020
Journal Articles

CD22 Expression Level As a Predictor of Survival in Patients (Pts) with Relapsed/Refractory (R-R) Acute Lymphoblastic Leukemia (ALL) Treated with Inotuzumab Ozogamicin (INO) in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) with or without Blinatumomab: Results from a Phase 2 Study

Hind Rafei, MD, Hagop M. Kantarjian, MD, Koji Sasaki, MD, Nicholas J. Short, MD, Farhad Ravandi, MBBS, Xuelin Huang, PhD, Joseph D. Khoury, MD, Sa A Wang, MD, Jeffrey L. Jorgensen, MD PhD, Issa F. Khouri, MD, Partow Kebriaei, MD, Nitin Jain, MD, Bouthaina S. Dabaja, MD, Lucia Masarova, MD, Tapan M. Kadia, MD, Shilpa Paul, PharmD, Dan Nichols, Guillermo Garcia-Manero, MD, Jan A. Burger, MD PhD, Courtney D. DiNardo, MD MSCE, Naval Daver, MD, Guillermo Montalban-Bravo, MD, Musa Yilmaz, MD, Prithviraj Bose, MD, Rita Khouri, Philip A. Thompson, MB, MS, Jovitta Jacob, Meagan Rostykus, RN, Rebecca Garris, MSc, Marina Konopleva, MD PhD, Susan M. O'Brien, MD, Elias Jabbour, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 23–25.
https://doi.org/10.1182/blood-2020-143400
Published: 2020
Journal Articles

Long-Term Follow-up of the Combination of Low-Intensity Chemotherapy Plus Inotuzumab Ozogamicin with or without Blinatumomab in Patients with Relapsed-Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Phase 2 Trial

Koji Sasaki, MD, Hagop M. Kantarjian, MD, Farhad Ravandi, MBBS, Nicholas J. Short, MD, Partow Kebriaei, MD, Xuelin Huang, PhD, Nitin Jain, MD, Marina Konopleva, MD PhD, Guillermo Garcia-Manero, MD, Richard E. Champlin, MD, Tapan M. Kadia, MD, Koichi Takahashi, MD PhD, Naval Daver, MD, Hind Rafei, MD, Joseph D. Khoury, MD, Jeffrey L. Jorgensen, MD PhD, Sa A Wang, MD, Maria R Khouri, Jovitta Jacob, Rebecca Garris, MSc, Susan M. O'Brien, MD, Elias Jabbour, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 40–42.
https://doi.org/10.1182/blood-2020-139896
Published: 2020
Journal Articles

A Prognostic Model for Survival in Patients with Relapsed/Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia on the Combination of Low-Intensity Chemotherapy Plus Inotuzumab Ozogamicin with or without Blinatumomab

Koji Sasaki, MD, Hagop M. Kantarjian, MD, Farhad Ravandi, MBBS, Nicholas J. Short, MD, Partow Kebriaei, MD, Xuelin Huang, PhD, Nitin Jain, MD, Marina Konopleva, MD PhD, Guillermo Garcia-Manero, MD, Richard E. Champlin, MD, Tapan M. Kadia, MD, Koichi Takahashi, MD PhD, Hind Rafei, MD, Sa A Wang, MD, Joseph D. Khoury, MD, Jeffrey L. Jorgensen, MD PhD, Maria Khouri, Jovitta Jacob, Rebecca Garris, MSc, Susan M. O'Brien, MD, Elias Jabbour, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 2–4.
https://doi.org/10.1182/blood-2020-140037
Published: 2020
Journal Articles

Sequential Combination of Inotuzumab Ozogamicin (InO) with Low-Intensity Chemotherapy (mini-hyper-CVD) with or without Blinatumomab (Blina) As Salvage Therapy for Patients (Pts) with Acute Lymphoblastic Leukemia (ALL) in First Relapse

Hind Rafei, MD, Hagop M. Kantarjian, MD, Koji Sasaki, MD, Nicholas J. Short, MD, Farhad Ravandi, MBBS, Xuelin Huang, PhD, Joseph D. Khoury, MD, Sa A Wang, MD, Jeffrey L. Jorgensen, MD PhD, Issa F. Khouri, MD, Partow Kebriaei, MD, Nitin Jain, MD, Bouthaina S. Dabaja, MD, Yesid Alvarado, MD, Tapan M. Kadia, MD, Shilpa Paul, PharmD, Serena Chew, PharmD, Guillermo Garcia-Manero, MD, Jan A. Burger, MD PhD, Courtney D. DiNardo, MD MSCE, Naval Daver, MD, Guillermo Montalban-Bravo, MD, Musa Yilmaz, MD, Maro Ohanian, DO, Maria Khouri, Philip A. Thompson, MB, MS, Jovitta Jacob, Meagan Rostykus, RN, Rebecca Garris, MSc, Marina Konopleva, MD PhD, Susan M. O'Brien, MD, Elias Jabbour, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 36–38.
https://doi.org/10.1182/blood-2020-143386
Published: 2020
Journal Articles

Roleof Allogeneic Stem Cell Transplant (ASCT) in Patients (Pts) with Relapsed/Refractory (R-R) Acute Lymphoblastic Leukemia (ALL) Treated with Inotuzumab Ozogamicin (INO) in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) with or without Blinatumomab (Blina): Results from a Phase 2 Study

Hind Rafei, MD, Hagop M. Kantarjian, MD, Koji Sasaki, MD, Nicholas J. Short, MD, Farhad Ravandi, MBBS, Xuelin Huang, PhD, Joseph D. Khoury, MD, Sa A Wang, MD, Jeffrey L. Jorgensen, MD PhD, Issa F. Khouri, MD, Partow Kebriaei, MD, Richard E. Champlin, MD, Nitin Jain, MD, Bouthaina S. Dabaja, MD, Ghayas C. Issa, MD, Naveen Pemmaraju, MD, Tapan M. Kadia, MD, Shilpa Paul, PharmD, Nadya Jammal, PharmD, Guillermo Garcia-Manero, MD, William G. Wierda, MD PhD, Courtney D. DiNardo, MD MSCE, Naval Daver, MD, Guillermo Montalban-Bravo, MD, Rita Khouri, Patrice Nasnas, MD, Philip A. Thompson, MB, MS, Jovitta Jacob, Meagan Rostykus, RN, Rebecca Garris, MSc, Marina Konopleva, MD PhD, Susan M. O'Brien, MD, Elias Jabbour, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 39–41.
https://doi.org/10.1182/blood-2020-143286
Published: 2020
Journal Articles

Impact of Cytogenetic Abnormalities (CA) on Outcome of Patients (Pts) with Relapsed/Refractory (R-R) Acute Lymphoblastic Leukemia (ALL) Treated with Inotuzumab Ozogamicin (INO) in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) with or without Blinatumomab: Results from a Phase 2 Study

Hind Rafei, MD, Hagop M. Kantarjian, MD, Koji Sasaki, MD, Nicholas J. Short, MD, Farhad Ravandi, MBBS, Xuelin Huang, PhD, Joseph D. Khoury, MD, Sa A Wang, MD, Jeffrey L. Jorgensen, MD PhD, C. Cameron Yin, MD PhD, Issa F. Khouri, MD, Partow Kebriaei, MD, Nitin Jain, MD, Koichi Takahashi, MD PhD, Bouthaina S. Dabaja, MD, Srdan Verstovsek, MD PhD, Tapan M. Kadia, MD, Shilpa Paul, PharmD, Caitlin R. Rausch, PharmD, Guillermo Garcia-Manero, MD, William G. Wierda, MD PhD, Courtney D. DiNardo, MD MSCE, Naval Daver, MD, Guillermo Montalban-Bravo, MD, Musa Yilmaz, MD, Patrice Nasnas, MD, Rita Khouri, Monica Kwari, BSN, Jovitta Jacob, Meagan Rostykus, RN, Rebecca Garris, MSc, Marina Konopleva, MD PhD, Susan M. O'Brien, MD, Elias Jabbour, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 45–47.
https://doi.org/10.1182/blood-2020-143401
Published: 2020
Journal Articles

Updated Results of a Phase II Study of Reduced-Intensity Chemotherapy with Mini-Hyper-CVD in Combination with Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia

Nicholas J. Short, MD, Hagop M. Kantarjian, MD, Farhad Ravandi, MD, Xuelin Huang, PhD, Nitin Jain, MD, Koji Sasaki, MD, Rita Khouri, Naval G. Daver, MD, Naveen Pemmaraju, MD, Joseph D. Khoury, MD, Jeffrey L. Jorgensen, MD PhD, Yesid Alvarado, MD, Marina Y Konopleva, MD PhD, Guillermo Garcia-Manero, MD, Tapan M. Kadia, MD, Musa E. Yilmaz, MD, Gautam M. Borthakur, MD, Jan A. Burger, MD PhD, Steven M. Kornblau, MD, William G. Wierda, MD PhD, Courtney D. DiNardo, MD MSc, Alessandra Ferrajoli, MD, Jovitta Jacob, RN, Meagan Rostykus, RN, Rebecca Garris, MSc, Marygrace Ward, RDC, Binru Huang, RDC, Corabelle Encarnacion, RDC, Christopher Loiselle, BS, Susan M. O'Brien, MD, Elias Jabbour, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 823.
https://doi.org/10.1182/blood-2019-125136
Published: 2019
Journal Articles

Prognostic Factors for Progression in Patients (pts) with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) in Complete Molecular Response (CMR) within 3 Months of Therapy with Tyrosine Kinase Inhibitors (TKIs)

Koji Sasaki, MD, Hagop M. Kantarjian, MD, Bachar Samra, MD, Nicholas J. Short, MD, Joseph D. Khoury, MD, Rashmi Kanagal-Shamanna, MD, Marina Y Konopleva, MD PhD, Nitin Jain, MD, Courtney D. DiNardo, MDMSc, Rita Khouri, Guillermo Garcia-Manero, MD, Tapan M. Kadia, MD, William G. Wierda, MD PhD, Nicole Tippett, RN, Rebecca Garris, MSc, Victoria Jeanis, RN, Naval G. Daver, MD, Philip A. Thompson, MBBS, Musa Yilmaz, MD, Jorge E. Cortes, MD, Susan M. O'Brien, MD, Farhad Ravandi, MD, Elias Jabbour, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1296.
https://doi.org/10.1182/blood-2019-128619
Published: 2019
Journal Articles

The Early Achievement of Measurable Residual Disease Negativity in the Treatment of Adults with Philadelphia-Negative B-Cell Acute Lymphoblastic Leukemia Is a Strong Predictor for Survival

Musa Yilmaz, MD, Hagop M. Kantarjian, MD, Xuemei Wang, MS, Joseph D. Khoury, MD, Farhad Ravandi, MD, Jeffrey L. Jorgensen, MD PhD, Nicholas J. Short, MD, Sanam Loghavi, MD, Jorge E. Cortes, MD, Guillermo Garcia-Manero, MD, Tapan M. Kadia, MD, Koji Sasaki, MD, Marina Y Konopleva, MD PhD, Koichi Takahashi, MD, William G. Wierda, MD PhD, Nitin Jain, MD, Srdan Verstovsek, MD PhD, Zeev E. Estrov, MD, Prithviraj Bose, MD, Sherry A. Pierce, BSN, BA, Rebecca Garris, MSc, Susan M. O'Brien, MD, Elias Jabbour, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1297.
https://doi.org/10.1182/blood-2019-125913
Published: 2019
Journal Articles

Prognostic Significance of IKZF1 , PAX5 , and CDKN2A Deletions in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Treated with Hyper-CVAD/MA with Dasatinib or Ponatinib

Yuya Sasaki, MD PhD, Nicholas J. Short, MD, Hagop M. Kantarjian, MD, Rebecca Garris, MSc, Nitin Jain, MD, Koji Sasaki, MD, Farhad Ravandi, MD, Marina Y Konopleva, MD PhD, Michael E. Rytting, MD, Guillermo Garcia-Manero, MD, Latasha Little, BS, Curtis Gumbs, Li Zhao, PhD, P. Andrew Futreal, PhD, Feng Wang, PhD, Koichi Takahashi, MD, Elias Jabbour, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2753.
https://doi.org/10.1182/blood-2019-122017
Published: 2019
Journal Articles

Phase II Study of the Hyper-CVAD Regimen in Combination with Ofatumumab (HCVAD-O) As Frontline Therapy for Adult Patients (pts) with CD20-Positive B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Guillaume Richard-Carpentier, MD, Hagop M. Kantarjian, MD, Marina Y Konopleva, MD PhD, Keyur P. Patel, MBBS, PhD, Kathryn G. Roberts, PhD, Zhaohui Gu, PhD, Farhad Ravandi, MD, Nitin Jain, MD, Nicholas J. Short, MD, Guillermo Garcia-Manero, MD, Heather M Schroeder, Monica Kwari, BSN, Rebecca Garris, MSc, Rita Khouri, Mike Jones, RDC, Christopher Loiselle, BS, Jorge E. Cortes, MD, Koji Sasaki, MD, Ghayas C. Issa, MD, Tapan M. Kadia, MD, Courtney D. DiNardo, MDMSc, Srdan Verstovsek, MD PhD, Naval G. Daver, MD, Charles G. Mullighan, MBBS, MD, Susan M. O'Brien, MD, Elias Jabbour, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2577.
https://doi.org/10.1182/blood-2019-129884
Published: 2019
Journal Articles

Ultra-Accurate Assessment of Pretreatment ABL1 Kinase Domain (KD) Mutations in Patients (pts) with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Using Duplex Sequencing (DS)

Nicholas J. Short, MD, Hagop M. Kantarjian, MD, Rashmi Kanagal-Shamanna, MD, Koji Sasaki, MD, Farhad Ravandi, MD, Jorge E. Cortes, MD, Marina Y Konopleva, MD PhD, Ghayas C. Issa, MD, Steven M. Kornblau, MD, Guillermo Garcia-Manero, MD, Victor Rivera, PhD, Rebecca Garris, MSc, Jacob Higgins, PhD, Gabriel Pratt, PhD, Lindsey N. Williams, PhD, Charles C. Valentine, MS, Jesse J. Salk, MD PhD, Justin Prichard, PhD, Jerald P. Radich, MD, Elias Jabbour, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2578.
https://doi.org/10.1182/blood-2019-125131
Published: 2019
Journal Articles

Characteristics and Clinical Outcomes of Patients with Acute Lymphoblastic Leukemia with KMT2A ( MLL ) Rearrangement

Guillaume Richard-Carpentier, MD, Hagop M. Kantarjian, MD, Guilin Tang, MD, C. Cameron Yin, MD PhD, Joseph D. Khoury, MD, Ghayas C. Issa, MD, Nitin Jain, MD, Farhad Ravandi, MD, Nicholas J. Short, MD, Courtney D. DiNardo, MDMSc, Koichi Takahashi, MD, Maro Ohanian, DO, Gautam M. Borthakur, MD, Marina Y Konopleva, MD PhD, Naval G. Daver, MD, Zeev E. Estrov, MD, Yesid Alvarado, MD, Alessandra Ferrajoli, MD, Tapan M. Kadia, MD, Guillermo Garcia-Manero, MD, Srdan Verstovsek, MD PhD, Rebecca Garris, MSc, Jorge E. Cortes, MD, Susan O'Brien, MD, Elias Jabbour, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2582.
https://doi.org/10.1182/blood-2019-130864
Published: 2019
Journal Articles

Inotuzumab Ozogamicin (Ino) May Overcome the Impact of Philadelphia Chromosome (Ph)-like Phenotype in Adult Patients (pts) with Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL)

Elias Jabbour, MD, Kathryn G. Roberts, PhD, Koji Sasaki, MD, Yaqi Zhao, MSc, Chunxu Qu, PhD, Zhaohui Gu, PhD, Nitin Jain, MD, Keyur P. Patel, MBBS, PhD, Farhad Ravandi, MD, Nicholas J. Short, MD, Guillermo Garcia-Manero, MD, Rebecca Garris, MSc, Steven Kornblau, Marina Y Konopleva, MD PhD, Charles G. Mullighan, MBBS, MD, Hagop M. Kantarjian, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1641.
https://doi.org/10.1182/blood-2019-126940
Published: 2019
Journal Articles

Sequential Combination of Inotuzumab Ozogamicin (InO) with Low-Intensity Chemotherapy (Mini-hyper-CVD) with or without Blinatumomab Is Highly Effective in Patients (pts) with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL) in First Relapse

Koji Sasaki, MD, Hagop M. Kantarjian, MD, Farhad Ravandi, MD, Nicholas J. Short, MD, Partow Kebriaei, MD, Xuelin Huang, PhD, Michael E. Rytting, MD, Nitin Jain, MD, Marina Y Konopleva, MD PhD, Guillermo Garcia-Manero, MD, Richard E. Champlin, MD, Tapan M. Kadia, MD, Jorge E. Cortes, MD, Zeev E. Estrov, MD, Koichi Takahashi, MD, Christopher Loiselle, BS, Corabelle Encarnacion, RDC, Meagan Rostykus, RN, Rita Khouri, Patrice Nasnas, MD, Jovitta Jacob, RN, Monica Kwari, BSN, Rebecca Garris, MSc, Elias Jabbour, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3806.
https://doi.org/10.1182/blood-2019-129018
Published: 2019